Discoveries · Boston and London
Viagra-like pill AR1001 slows early Alzheimer's decline by 31% in trial subgroup
AriBio's once-daily tablet AR1001 slowed cognitive decline by 31% over a year in 604 early-stage patients not taking other Alzheimer's drugs. The effect was not statistically significant in patients already on other treatments.
AI text based on reports by Stirile ProTV, Washington Post, LBC and other publishers. Published . How it is made
For membersThe first 30 seconds for everyone. Synthetic voice (AI).
In brief
Among 604 participants not taking other Alzheimer's drugs, cognitive decline over one year ran 31% slower on AR1001 than on the placebo tablet, according to AriBio.
Patients already on other Alzheimer's treatments, about 60% of the 1,535-person study population, showed no statistically significant benefit, so the effect disappeared across the full group.
AriBio plans to ask the FDA whether the current data can stand on their own or whether another trial will be needed.
Richard Oakley of the Alzheimer's Society said the drug needs further investigation, while Atticus Hainsworth of City St George's, University of London, said it is early days.
The trial and its design
AriBio, a South Korean company, reported topline results from a year-long trial of AR1001 in people with early-stage Alzheimer's disease. The study enrolled 1,535 participants from 13 countries, including the United Kingdom. Some received AR1001 while others took a tablet without active ingredient for comparison. Over the year, researchers tracked memory, thinking ability and the capacity to manage everyday activities. The findings were presented at the Clinical Trials on Alzheimer's Disease conference in Boston, United States.
- Full trial population
- 1535 people
- Not taking other Alzheimer's drugs
- 604 people
Data from the article text
Results in patients not on other drugs
The strongest signal came from 604 participants who were not taking other medicines for Alzheimer's. In that group, cognitive decline progressed 31% more slowly on AR1001 than on the placebo tablet over one year. The company estimated that after a year, the treated group was roughly where the placebo group had been about 3½ months earlier. This subgroup made up about 40% of the study population. Outcomes were measured through interviews with patients and caregivers about memory, judgment and the ability to handle daily life. Researchers have not yet established why the drug worked in this group but not in the other.
A mixed result across the full trial
Patients already taking standard Alzheimer's treatments, about 60% of the study population, showed little to no benefit from AR1001. The drug did not reach statistical significance in that wider group. Because the effect vanished across the full population, the overall picture is less clear than the subgroup figure suggests. AriBio had set out in advance that it would judge the results both across everyone and in the group not taking other dementia medicines, and a win in either would count as meeting the main goal. The company describes the outcome as a success.
Expert reaction and caveats
Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, called the topline results an encouraging sign.
“These topline results are an exciting sign that we could have a totally new treatment for early Alzheimer's disease that tackles its causes, not just its symptoms.”
Oakley noted that the tablet is taken once a day and works by relaxing blood vessels to increase blood flow to the brain. He said the drug appears less effective for people on other Alzheimer's symptom drugs and needs further investigation. He also warned that people should not take Viagra to treat Alzheimer's, and that AR1001 is not yet available to the public and needs approval from UK regulators. Atticus Hainsworth, a neuroscientist at City St George's, University of London, who was not involved in the study, was also cautious.
“It's early days to say much definitively”
Mechanism and next steps
AR1001 contains mirodenafil, a substance used in developing erectile dysfunction medicines and belonging to the same drug class as Viagra. Both block an enzyme called PDE5, which relaxes blood vessels and improves circulation. The trial tested a lower-dose formulation of Mvix, a product already sold in South Korea for erectile dysfunction. AriBio plans to ask the FDA whether the existing data are sufficient or whether another trial will be required. Full results are still awaited.
Ask about this text
Sources and context
- Stirile ProTVA drug also called “Viagra for the brain” could slow the progression of Alzheimer's disease. What researchers discoveredUn medicament numit și "Viagra pentru creier" ar putea încetini evoluția bolii Alzheimer. Ce au descoperit cercetătorii · original in Romanian
- Washington PostThe first pill to slow Alzheimer's could come from an unexpected place
- LBCDrug that works in similar way to Viagra 'could slow down' Alzheimer's decline
- The TelegraphViagra-like drug slows Alzheimer's in some patients
- Places
- Boston, London, South Korea
Pollar is free and carries no ads in the text. Its members keep it going.
Support Pollar